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Gray Matter Atrophy Associated With Motor Dysfunction
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Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder with common symptoms
including rigidity, tremors, and bradykinesia.
While current medication can alleviate symptoms, no treatment exists to stop or slow neuronal cell death and disease progression. There is
an unmet need for a biomarker associated with
progression that could aide in development of
treatments by monitoring disease progression.
Since Magnetic Resonance Imaging (MRI) allows for the measure of gray matter (GM) density
in the human brain noninvasively, this study was
designed to investigate the association between
brain atrophy, measured by MRI, and motor dysfunction in PD subjects, as a biomarker.
MRI and voxel-based morphometry methods were
used to investigate GM atrophy and the association
with motor impairment in 43 PD and 59 control
subjects. T1-weighted whole-brain MRI images
were acquired in collaborative studies in Germany
and at Indiana University on 3T MRI scanners.
Group differences in GM density between PD and
control subjects were examined voxel by voxel
with SPM12 using cluster-corrected two-sample
t-tests. Among PD subjects, associations of GM
density with motor dysfunction (measured by UPDRS-III) were analyzed by multiple regression.
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Parkinson’s disease (PD) is one of the most common
neurodegenerative diseases with symptoms including tremor, bradykinesia (slowness of movement),
rigidity, and impaired posture control (Miller &
O’Callaghan, 2015). PD is characterized by the loss
of dopaminergic neurons in the substantia nigra,
but neurodegeneration is more widespread. While
medication can alleviate certain PD symptoms, no
treatment exists to slow the disease progression.
Therefore, there is a great need for the development
of a treatment method that can help slow down or
reverse the neurodegeneration incurring among
PD patients. Typically, a PD diagnosis is based on
observed symptoms in the clinic, such as using
the Unified Parkinson’s disease Rating Scale
(UPDRS-III) which measures motor impairment.
Yet, there is no objective biomarker that allows
diagnosis or monitoring of disease progression for
PD patients.
In recent years, medical imaging techniques have
made advances as a potential solution to diagnose
and monitor treatment strategies. In particular,
Magnetic Resonance Imaging (MRI), which provides
multiple contrasts and functional information, may
provide more information regarding the pathological
process of neurodegenerative diseases like PD.
Voxel-based morphometry (VBM) enables a wholebrain voxel-wise comparison of gray matter (GM)
and white matter (WM) using MRI images. A voxel
refers to a small volume of space, often used in
imaging or three-dimensional modeling. VBM can
help characterize and identify subtle changes in brain
structures in a wide variety of neurologic and psychiatric dysfunction diseases. Since VBM measures
the density of GM in the brain, that is, is a measure
of neuronal density, it should be a suitable tool to
measure neurodegeneration and its progression in
PD. All subcortical areas commonly associated with
PD, including the caudate nucleus, the putamen, the
globus pallidus, the subthalamic nucleus, and the
substantia nigra, have been found to show significant
atrophy using VBM (Lin et al., 2013). However, these
changes have not been sensitive enough to serve as
biomarker of progression for PD. Moreover, it has
been shown that a high concentration of iron leads to
incorrect classification of tissues in these subcortical
structures (Lorio et al., 2016).
Recently, literature has also shown GM atrophy
present in cortical brain areas that are not typically
associated with PD, including the frontal lobe,
intraparietal sulcus, the temporal lobe, parietal
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Compared to controls, PD subjects show significant GM atrophy in the supplementary motor
cortex (p < 0.005). This is a critical brain region,
linking cognition to action. Among PD subjects,
there is a significant association (p < 0.001)
of GM atrophy with motor dysfunction (high
UPDRS-III) bilaterally in the superior parietal
lobules of the motor cortex. These findings agree
with the hypothesis that motor dysfunction is
associated with GM atrophy in the motor cortex,
and that imaging GM density by MRI is a good
display of neurodegenerative progression in PD.

INTRODUCTION

stimulated by the environment. Figure 1 maps
these two loops. Being able to noninvasively study
progressive changes in GM density associated to
these motor loops is therefore of particular interest
in monitoring PD patients.

AIMS/PURPOSE
There is an unmet need for an objective biomarker
associated with progression of disease—in particular
with worsening motor function. If sensitive enough,
such a biomarker could even allow intervention at
the onset of disease before severe symptoms appear.
It could also help with early diagnosis of atypical
parkinsonism, which requires different treatment, or
help to monitor disease modifying therapy (Miller &
O’Callaghan, 2015).
Figure 1. Summary of motor loops, connecting cortical
and subcortical brain regions.

lobe, and occipital lobes (Burton, McKeith, Burn,
Williams, & O’Brien, 2004; Lee et al., 2014;
Weintraub et al., 2012; Melzer et al., 2012; Sterling
et al., 2017). However, results were inconsistent.
The discrepancies across studies may be due to
inhomogeneous subjects, such as the heterogeneity
amongst different subtypes of parkinsonism,
displaying different types of symptoms.
Since PD is classified as a movement disorder, most
damage has been found in motor loops of the central
nervous system (Draganski & Bhatia, 2010). These
motor loops connect the subcortical brain regions
commonly associated with PD to cortical brain
regions executing movement and cognition. First,
the basal ganglia-thalamocortical loop interconnects
the structures of the basal ganglia (including the
substantia nigra), the prefrontal cortex, and the supplementary motor cortex (Ash et al., 2011). This loop
and associated brain regions are very important for
motor behavior. An additional pathway to consider
is the cerebello-thalamocortical loop connecting the
prefrontal cortex, the thalamus, and the cerebellum.
This pathway plays a key role to regulate actions

Therefore, the purpose of this present study was to
evaluate the relationship between GM atrophy in
PD patients compared to control subjects, and how
it relates to motor dysfunction. VBM was used to:
(1) assess the difference in GM density between
PD patients and control subjects and (2) investigate
differences in GM density with decreased motor
function across PD patients.

METHODS
Voxel-Based Morphometry (VBM)
MRI is used to study structural changes in the brain.
VBM is a neuroimaging analysis technique that
allows the investigation of structural changes in the
brain using statistical parameter mapping. In this
study, VBM was used to investigate changes in GM
density in PD patients and associations with motor
impairment in PD.

Subjects
A total of 43 PD patients and 59 controls were used
in this analysis. All patients and controls in the study
were male. MRI data was obtained from two collaborative PD studies: 24 PD patients and 43 controls
were recruited at Ruhr University in Bochum, Germany. Nineteen PD patients and sixteen controls were

Study

Scanner

Subjects

Median Age (Years)

Median UPDRS-III

Ruhr University,
Bochum, Germany

3T Philips Achieva

PD n = 24

62

30

Controls n = 43

59

1

Indiana University,
Indianapolis, Indiana

3T Siemens Trio

PD n = 19

63

31

Controls n = 16

58

3

Table 1. PD and control subject demographics.
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studied at Indiana University School of Medicine
(IUSM) in Indianapolis, Indiana. Demographics of
subjects are summarized in Table 1.

Motor Dysfunction Assessment
To assess individual motor function, all subjects
were scored by certified neurologists using the motor
part of the Unified Parkinson Disease Rating Scale
(UPDRS-III), which assesses the ability to perform
various motor tasks. A higher UPDRS-III score
indicates increased motor impairment. It should be
noted that PD patients from Bochum were taking
medication, which may influence their UPDRS-III
scores, whereas patients in the study at IUSM were
either medication-naïve or withheld medication for
at least 12 hours prior to their UPDRS-III evaluation
and MRI scans.

Figure 2. SPM12 processing sequence.

MRI
High resolution T1-weighted magnetic resonance
images (MPRAGE) were acquired on 3.0 Tesla
whole-body MRI systems for all subject groups.
T1-weighted MRI’s provide tissue contrast,
which is useful when distinguishing GM, WM,
and cerebrospinal fluid (CSF). Data was acquired
on a Philips Achieva MRI system at Bochum and on
a Siemens TIM Trio system at IUSM. Imaging parameters included TR/TE = 8.3/2.7 milliseconds and
an acquisition matrix of 240x240x240, yielding a
resolution of 1x1x1 mm3. Each complete whole-brain
MRI scan contained 220 slices.

Data Analysis

The SPM output is given as spatial x, y, z coordinates of voxels, each associated with a proportional
density of GM within the voxel. This method allows
a voxel-by-voxel statistical comparison across a large
sample of MR images. SPM12 also allows the display
of neuromorphometric regions in which the user can
identify a coordinate-based brain region related to
significant findings as part of the statistical analysis.

Statistical Analysis
An SPM12 significance map is created to identify
and highlight areas of statistical significance depending on the user-defined threshold. To analyze GM
differences between 43 PD patients and 59 normal
control subjects, a two-sample t-test was performed
with age and intracranial volume as covariates. For
the group difference, the significance was set to
p < 0.005. To account for multiple comparisons
across the many voxels, a cluster size threshold of
> 200 voxels was set.
To investigate an association between GM atrophy
and motor dysfunction, a multiple regression analysis
was completed across the 43 PD subjects and their
UPDRS-III scores, correcting for age and intracranial
37
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To determine GM density, Statistical Parameter
Mapping (SPM12) Functional MRI software was
used in conjunction with MATLAB to determine
GM density. The flowchart in Figure 2 outlines
the process. The T1-weighted images acquired in
Bochum and Indianapolis were first coregistered
into the same imaging plane, which places all
images in the same orientation. Next, images
were segmented into GM, WM, and CSF on a
voxel-by-voxel basis, analyzing image contrast. As
a result, a probability map is created proportional
to the density of GM, WM, and CSF in each voxel.
Images are then normalized to a standard brain atlas,
retaining individual GM, WM, and CSF probabilities. Finally, an 8mm full-width-at-half-maximum
(FWHM) Gaussian kernel filter was applied. This
spatial smoothing is set to remove noise and random
signal, increasing the validity of SPM12. Figure 3
exemplifies the transition of the original T1-weighted
image before and after processing.

Figure 3. Left: Original sagittal T1-weighted MRI;
Middle: T1-weighted MR image after segmentation, normalization, and smoothing; Right: T1 template image.

volume. A significance threshold of p < 0.001 with a
cluster size > 200 voxels was used.

RESULTS
Group Differences
Compared to normal controls, a significant
(p < 0.005, cluster size > 200) GM atrophy was found
in PD patients in the left supplementary motor cortex
of the frontal lobe. Figure 4 highlights the GM differences on a T1-weighted overlay.

Figure 4. Group differences: Compared to controls,
significant GM atrophy is seen in the left supplementary
motor cortex of PD patients (p-value < 0.005, cluster
size > 200).

Regression with Motor Dysfunction
Among PD subjects there is a significant (p < 0.001,
cluster size > 200) association of GM atrophy with
increased UPDRS-III scores in the right and left superior parietal lobules of the motor cortex as shown
in Figure 5.

Figure 5. Regression with motor function: Within PD
subjects lower motor performance (higher UPDRS-III
score) correlated with lower GM density in the left and
right superior parietal lobes of the motor cortex (p-value < 0.001, cluster size > 200).

DISCUSSION
Our analysis revealed differences among PD and
control subjects in the supplementary motor cortex.
The supplementary motor cortex is a critical brain
region that works to link cognition to action (Nachev,
Kennard, & Husain, 2008). These findings are in line
with previous literature showing GM atrophy in the
frontal lobe and supplementary motor cortex across
PD patients (González-Redondo et al., 2014).
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Additionally, our findings agreed with the hypothesis that motor dysfunction is associated with GM
atrophy in the motor cortex in PD patients. Our
results are in line with a previous study that has seen
significant GM atrophy in the motor cortex being associated with disease severity (Wu & Hallett, 2005).
Atrophy in these brain regions could also explain
that, compared to normal subjects, PD patients have
been shown to have less neural activity in the parietal
lobules of the motor cortex (Zhang et al., 2015).
As previously discussed, the supplementary motor
cortex is a part of the basal ganglia-thalamocortical
loop. Activation of this loop is important for voluntary movement. With a loss of neuronal function in
the supplementary motor cortex due to GM atrophy
(i.e., loss of neurons), these findings indicate that GM
atrophy could be related to voluntary motor control
in PD. Therefore, these findings agree with the hypothesis that severity of PD motor symptoms can be
associated with GM atrophy.

Limitations of our Study: Experimental Design
In order to increase the sample size for statistical
comparison, we pooled two studies, which bears its
own limitations. For example, the 16 healthy controls
from the IUSM study had a relatively high median
UPDRS-III score of 3, as was noted in Table 1. Ideally, a healthy control should have a very low rating
(less than 2) on a UPDRS-III scale, which might
slightly increase with age. The difference could be
due to a scoring inconsistency between the raters of
the two studies which could alter the group difference analysis. In future studies, the same rater should
be scoring all subjects to avoid such inconsistencies.
Furthermore, the Bochum PD patients were not withholding medication at the time of the study, as did
the IUSM PD patients. This may have an effect on
their UPDRS-III scores, which could have an impact
on the regression with motor dysfunction findings.
Additionally, the Bochum control subjects were not
matched in socioeconomic background and education
due to recruitment via newspaper advertisements.
Alcohol and substance abuse may additionally have
been a confounding variable.
Finally, the sample size in this study was relatively
limited. Increasing the sample size could improve the
accuracy and validity of the results.

Limitations of Voxel-Based Morphometry
With respect to the use of VBM, many studies show
variable results. Despite the potential of using VBM
as a biomarker of progression of neurodegeneration,

there are numerous drawbacks that may impede its
usefulness in the clinic at this time. For example, GM
atrophy in PD patients is very small, less than a few
percent difference at onset of disease (Ash et al., 2011).
More progressed disease may see more advanced
degeneration. For this reason, it is essential to improve
accuracy and reduce sources of error in volumetry
techniques to produce reliable conclusions.
Moreover, the coherence across VBM studies is lacking, especially in neurodegenerative diseases like PD.
Some studies have shown a wide range of GM atrophy
across several brain regions, while others find no significant differences. The large range in findings is not
unexpected, as long as PD patients are not stratified for
their diverse symptoms (for example, with or without
dementia, etc.) and potential for atypical PD. These different clinical symptoms rely on many different brain
regions associated with motor control and cognitive
processing of voluntary movement and may thus affect
these brain regions differently in these subpopulations.
If obstacles such as these are overcome, VBM may
prove to become a successful biomarker in PD and
other neurodegenerative diseases, helping in the
development of treatment options by being able to
objectively monitor progression of the disease, irrespective of medication status.

CONCLUSION
Overall, noninvasive MRI can be a useful tool to
identify GM atrophy in PD patients and changes in
GM density that are associated with specific symptoms, such as motor impairment, to serve as marker
of disease progression. Congruence among several
studies will validate results observed in this study
as well as previous literature. Our study is one step
toward this validation.
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